Gepotidacin - GSK
Alternative Names: Blujepa; GSK 2140944; GSK-2140944ELatest Information Update: 27 Mar 2025
At a glance
- Originator GSK
- Class Acenaphthenes; Anti-infectives; Antibacterials; Aza compounds; Ketones; Piperidines; Pyridines; Pyrones; Small molecules; Urinary anti-infective agents
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Urinary tract infections
- Phase III Gonorrhoea
- Discontinued Respiratory tract infections; Skin and soft tissue infections
Most Recent Events
- 27 Mar 2025 Discontinued - Phase-I for Respiratory tract infections (In volunteers) in Australia (IV)
- 27 Mar 2025 Discontinued - Phase-I for Respiratory tract infections (In volunteers) in Australia (PO)
- 27 Mar 2025 Discontinued - Phase-I for Respiratory tract infections (In volunteers) in United Kingdom (IV)